Stockreport

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF Unique mechanism of action, an intramolecular glue, locks the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) in a closed inactive state Phase 1 trial o [Read more]